This editorial refers to 'Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study' † , by J. Faber et al., on page 1555.
A rising incidence in paediatric cancers and improved long-term survival rates, reflective of substantial advances in paediatric oncology care, contribute to a growing population of childhood cancer survivors. Unfortunately, this cohort manifests excess cardiovascular (CV) risk throughout survivorship, and CV diseases eventually overtake subsequent primary cancers as the leading cause of premature mortality among ageing survivors of childhood cancer. 1 In this issue of the journal, Faber and co-investigators from the German Cardiac and Vascular Late Sequelae in Long-Term Survivors of Childhood Cancer (CVSS) study further our appreciation of the magnitude of this excess CV risk. 2 The CVSS-study investigators prospectively evaluated 1002 survivors, aged 23-48 years, who were treated prior their 15th birthday for childhood cancer between 1980 and 1990, using the same systematic standardized clinical and laboratory CV screening that was employed in the Gutenberg Health Study (GHS). Prevalence of CV risk factors and CV disease among survivors was compared with that of the GHS population, and with that of two further German population-based cohorts. The definition of CV disease was broad, including congestive heart failure, coronary heart disease, stroke, peripheral arterial disease, atrial fibrillation, and venous thrombo-embolism, determined by patient interview and supplemented with review of medical records. This cohort had an age-adjusted increased risk of 38% for the development of hypertension and 26% for dyslipidaemia compared with GHS participants. Hypertension and dyslipidaemia were each present in roughly a quarter of survivors, and occurred 6-8 years earlier than in the general population. At least one of the diseases included in the aggregate definition of CV disease was prevalent in 4.5% of survivors, with congestive heart failure and venous thrombo-embolism accounting for 64% of all CV disease. The risk of CV disease among survivors was almost twice (relative risk 1.89 , 95% confidence interval 1.34-2.66 ) that of the general population, with survivors developing CV disease on average 7.9 years prior to GHS participants. 2 The prospective and systematic phenotyping of survivors and comparison with control cohorts are welcome strengths of this study. Previous reports on the burden of CV disease in childhood cancer survivors have mostly relied on patient-reported outcomes and/or have failed to consider relevant controls. Another prospective evaluation from the St. Jude Lifetime Cohort Study of 1853 adult survivors of childhood cancer, that included fasting lipid panels, detected hypertension and dyslipidaemia in 23% and 62% of participants, respectively. 3 While the prevalence of hypertension is similar, the lower prevalence of dyslipidaemia in the CVSS-study is in part explained by different definitions of dyslipidaemia in the two studies. In addition, hypertension was defined as a systolic and/or diastolic blood pressure of > _140/90 mmHg in both studies, whereas application of lower cut-off points for hypertension of > _130/80 mmHg, endorsed by the 2017 American Heart Association/American College of Cardiology hypertension guideline, 4 would reclassify a significantly higher proportion of these survivors as hypertensive. Cardiovascular disease considered by Faber and colleagues focuses on reports of clinically manifest diagnoses only, and is exclusive of subclinical or undiagnosed overt CV injury (Take home figure) . Thus, the prevalence of 'CV disease' in this cohort is an underestimate of the true burden of CV disease when asymptomatic left ventricular (LV) dysfunction, valvular disease, pericardial disease, conduction disease, and silent coronary artery disease are considered. The CVSS-study investigators have tremendous potential for incremental phenotyping of this cohort by including additional CV testing such as echocardiography. Echocardiographic evaluation that 
included global longitudinal strain and diastolic function performed by the St. Jude Lifetime Cohort Study identified cardiac dysfunction in one-third of survivors with a normal LV ejection fraction. 5 However, these studies are limited by the cross-sectional, single time point nature of assessment, and future studies with serial testing over time are needed to help determine the natural history and adverse associations of these subclinical abnormalities among survivors. It should be noted that while Faber and colleagues identified a prevalence of dyslipidaemia in 28% and hypertension in 23%, only 11% of survivors were on any CV medication. 2 Although many factors contribute, use of pharmacological interventions in less than half of survivors with hypertension and/or dyslipidaemia is probably in part related to a reluctance to initiate drug therapy in younger patients (mean age of survivors in this cohort was 34 years Healthcare providers must empower survivors to share in the burden of CV surveillance, and have an ethical responsibility to counsel survivors on their CV vulnerability. A written summary of their cancer therapies and personalized recommendations for surveillance for late effects should be provided to all survivors. Survivors need to be informed of clinical signs and symptoms that should prompt medical review. In the current climate of stretched healthcare resources, survivors will need to become their own advocates for access to appropriate CV care. Optimization of modifiable CV risk factors should be a shared goal of survivors and their providers. Although the prevalence of smoking in the CVSS-study sample was significantly lower than in population-based cohorts, it is concerning that one-fifth of survivors were smokers. 2 This observation emphasizes the opportunity for health promotion among this cohort already predisposed to second malignancies and cardiac disease, for which smoking is a synergistic risk factor. Childhood cancer survivors represent a medically complex and currently underserved population at high risk of adverse CV outcomes. The specific healthcare needs of the growing cohort of ageing Take home figure Modifiers of the association of childhood cancer therapies and excess CV risk observed in adult survivors, together with promising strategies for risk reduction and inherent barriers to achieving reduction in CV risk. CV, cardiovascular; GLS, global longitudinal strain; RT, radiation therapy. 17 In addition, the potential impact of continued integration of newer biological and molecularly targeted agents, and immunotherapies, for treatment of childhood cancers on subsequent CV risk will require prospective evaluation. Furthermore, a growing appreciation among healthcare providers of the excess CV risk of survivors and improvements in their CV care should hopefully improve CV outcomes. While this work by Faber and colleagues reinforces the excess burden of CV risk factors and disease among childhood cancer survivors, future studies must now focus on the many knowledge gaps in mechanisms, diagnosis, screening, prevention, and management of CV injury in this cohort. Our understanding of the multifactorial pathobiology of premature CV disease in childhood cancer survivors that involves a complex interaction of cancer, cancer treatments, traditional CV risk factors, ageing, and genetics is incomplete. This deficiency has curtailed development of prevention strategies. Similarly, we lack a mechanistic approach for management of CV disease in survivors, and instead extrapolate treatment data from non-cancer cohorts. There is a pressing need for research to inform practice guidelines for screening, prevention, and management. There are now sufficient observational data that childhood cancer survivors represent a high-CV risk cohort that warrant more comprehensive care systems to improve CV outcomes. It is time to progress from risk observation to risk modification.
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